NICE green light for Cablivi in rare blood-clotting disorder
Treatment recommended for acquired thrombotic thrombocytopenic purpura
Read More
Tag: Cablivi
SMC accepts 14 new medicines for use by NHS Scotland
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read More
NICE rejects Sanofi’s Cablivi in draft guidelines
Trial data does not show whether adding Cablivi to standard care improves either length or quality of life over the long term, the Institute said
Read More
Cablivi gets FDA OK for blood clotting disorder
The US Food and Drug Administration (FDA) has approved Sanofi’s Cablivi as the first treatment for adult patients with a rare blood clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP).
Read More
Cablivi gets positive results for rare blood clotting disorder
Sanofi’s Cablivi has been linked with a 74% reduction in aTTP-related death in a Phase III trial published by the New England Journal of Medicine.
Read More
Sanofi’s Cablivi cleared for rare bleeding disorder
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Read More
CAR-T therapies leap towards EU approval
The stage has been set for approval of the first chimeric antigen T-cell therapies (CAR-T) in Europe, after Novartis’ Kymriah and Gilead’s Yescarta both won backing from the Committee for Medicinal Products for Human Use (CHMP).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
